Northwestern Mutual Wealth Management Co. Boosts Stock Holdings in Masimo Co. (NASDAQ:MASI)

Northwestern Mutual Wealth Management Co. grew its position in Masimo Co. (NASDAQ:MASI) by 133.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 350 shares of the medical equipment provider’s stock after acquiring an additional 200 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Masimo were worth $44,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Algert Global LLC purchased a new position in Masimo in the 2nd quarter valued at $1,748,000. Deerfield Management Company L.P. Series C acquired a new position in Masimo during the second quarter worth about $233,000. Point72 Hong Kong Ltd acquired a new position in Masimo during the second quarter worth about $3,183,000. Squarepoint Ops LLC purchased a new stake in Masimo during the 2nd quarter valued at about $1,220,000. Finally, Point72 Asset Management L.P. raised its holdings in Masimo by 107.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock valued at $85,347,000 after acquiring an additional 351,523 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Stock Down 1.0 %

Shares of MASI opened at $140.62 on Friday. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. The firm has a market cap of $7.48 billion, a P/E ratio of 95.66 and a beta of 0.99. The company’s 50-day moving average price is $123.11 and its 200 day moving average price is $125.27. Masimo Co. has a 12-month low of $75.22 and a 12-month high of $153.93.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The firm had revenue of $496.30 million for the quarter, compared to analyst estimates of $493.92 million. During the same period in the prior year, the business posted $0.62 EPS. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. On average, sell-side analysts forecast that Masimo Co. will post 3.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MASI has been the subject of a number of analyst reports. Piper Sandler upped their price target on Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.